Medical professionals are advising against undergoing a certain intimate cosmetic procedure purported to counteract what some claim is a ‘side effect’ of Ozempic.
Ozempic, a medication prescribed for managing Type 2 diabetes, aids the body by boosting insulin production when required, decreasing sugar production in the liver, and slowing the digestion of food.
Although its primary use is for treating Type 2 diabetes, Ozempic also makes users feel fuller on less food, which, when combined with a healthy lifestyle, can contribute to weight loss. However, it’s important to note that it is not officially approved as a weight loss drug.
Some individuals have reported online that their vulva appears ‘saggy’ after using the drug, leading to the term ‘Ozempic vagina’.
However, Ozempic’s manufacturer, Novo Nordisk, has clarified that this is not a documented side effect of the medication.
Despite this, some affected individuals are opting to spend approximately $2,000 on cosmetic surgery to receive fillers in their vulvas.
Dr. Michael Tahrey has noted that rapid weight loss from Ozempic could lead to fat reduction in the vulva area.
“In some women who take Ozempic, the rapid weight loss that occurs throughout the body may result in visible sagging of the labia or vagina because of overall fat and volume loss,” he stated.
“This sagging is caused by loose labia, loose skin in the vaginal area, wrinkles, or some combination of all three. It’s also common for rapid weight loss to cause the labia to suddenly feel out of proportion compared to how it previously felt.”
While some experts suggest that dermal fillers can enhance the appearance and function of tissues in that area, others caution about the potential dangers.
Professor Janice Rymer, a consultant gynaecologist and vice president of the Royal College of Obstetricians and Gynaecologists, expressed her ‘concern’ to The Sun about reports of genital cosmetic procedures.
“We are very concerned by reports of genital cosmetic procedures, including labia fillers and vaginal rejuvenation,” she commented.
“There is a significant lack of peer-reviewed medical research on the safety and efficacy of these procedures.
“As a result, doctors are unable to advise their patients on the risks, benefits or long-term consequences.”
Professor Rymer warned of possible severe outcomes, noting: “Complications may include infection, scarring, disfigurement and altered sensation of the labia which may interfere with normal sexual function.
“As with all cosmetic surgery, no procedure is without risk.”
A spokesperson for Novo Nordisk stated: “Patient safety is of the utmost importance to Novo Nordisk. We continuously collect safety data on our marketed medicines and work closely with the authorities to ensure patient safety.
“We recommend patients take these medications only for their approved indications and under the supervision of a healthcare professional.
“Treatment decisions should be made together with a healthcare provider who can evaluate the appropriateness of using a GLP-1 based on assessment of a patient’s individual medical profile.”